Exos Asset Management LLC
Filing Date
Global Rank
#8,035
/ 8,041
▼ 745
· as of Dec 2024
Top Industry
Medical Devices
100.0%
3Y Alpha vs SPY
-14.3%
Period ended 1 year ago
Filed Feb 13, 2025 · 1y
10 quarters · since Mar 2021
Clone Performance
Jul 2023–Jul 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+3.9%
SPY
+76.5%
Annualised alpha
-19.6%
Max drawdown
−67.6%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
1 positions · as of Dec 31, 2024 · Δ vs Sep 30, 2024Top Position
100.0%
0.0 pts
Top 5
100.0%
0.0 pts
Top 10
100.0%
0.0 pts
HHI
10,000
Highly concentrated0
Portfolio Trend
10 quarters · across all stocks
Sector Breakdown
As of Dec 31, 2024| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $18,056 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedNo qualifying positions this quarter.
Trimmed
Positions the filer reduced
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| TLSI | TriSalus Life Sciences, Inc. | −35,000 | 3,604 | $18,056 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarterNo qualifying positions this quarter.
Sold Out
Positions the filer fully exitedNo qualifying positions this quarter.
1 positions ·
$18,056 total
· as of Dec 31, 2024
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| TLSI |
TriSalus Life Sciences, Inc.
Healthcare
|
Reduced | 3,604 | $18,056 | 100.00% |